The Federal Trade Commission and seven states asked a federal court on October 13, 2026, to hold Martin Shkreli in civil contempt over alleged pharmaceutical stock trading. The Shkreli contempt dispute centers on whether those trades and related public commentary violated a lifetime industry ban imposed in 2022.

FTC Details the Alleged Shkreli Contempt

In its October 13 announcement, the FTC said Shkreli publicly traded pharmaceutical stocks and discussed those investments through social media posts and livestreams. The agency alleges that he bought and sold securities in at least 60 drugmakers, activity it says amounts to indirect participation in the pharmaceutical industry.

The lifetime ban followed a 2022 judgment in an antitrust case brought by the FTC and state partners. The court found that Shkreli helped run an unlawful scheme involving the drug Daraprim, whose list price rose from $17.50 to $750 per tablet, and ordered him to disgorge more than $64 million.

The new motion does not accuse the pharmaceutical companies whose shares were traded of wrongdoing. It focuses on whether Shkreli personally crossed the line set by the injunction, making the dispute different from company-centered enforcement matters such as the SEC judgment request involving Ken Leech.

Regulators Seek Divestment and Financial Sanctions

The FTC and the participating states asked the U.S. District Court for the Southern District of New York to require Shkreli to sell any pharmaceutical stocks he still owns. They also seek payment of profits from the alleged prohibited trades, plus prejudgment interest, without allowing losses on other trades to reduce that amount.

According to the agency, the requested order would establish escalating penalties if the court finds further violations. The FTC said those sanctions could eventually include incarceration, although a judge would determine any remedy and Shkreli can contest the allegations.

The commission approved the contempt action by a 1-0 vote, with Chairman Andrew Ferguson recused. The filing extends a run of federal competition and consumer-protection actions, including the FTC Gildan wholesale-pricing agreement and the joint FTC-USDA farm equipment inquiry.

What Investors Should Watch Next

The court must first assess the scope of the 2022 order and whether stock ownership, trading, or investment commentary qualifies as direct or indirect participation in the pharmaceutical industry. That legal question matters because broad industry bans can reach conduct beyond formal employment or corporate control.

For investors, the motion does not change the business outlook of the companies in Shkreli’s alleged portfolio. Its immediate significance is enforcement: the outcome may clarify how courts police lifetime market-participation restrictions and calculate gains when a defendant made both winning and losing trades.

The underlying FTC Daraprim case record contains the original orders and litigation history. No contempt finding had been entered when the agency announced the motion on October 13.

Featured image: Myriam Zilles via Unsplash.

Sharron Kendi is a seasoned crypto market analyst and writer with over three years of experience decoding blockchain trends, price movements, and market dynamics. She holds a Bachelor’s Degree in Commerce (Finance) from Kenyatta University, blending a solid academic foundation with a sharp eye for technical analysis and a deep understanding of on-chain data. Her work delivers clear, data-driven insights that empower investors to navigate the fast-evolving digital asset space with confidence.